Sign in

Back to the bill

91st General Assembly · Funnel one-pager · Monday, November 9, 2026

SF 433: Relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission

Died when the session ended · The 2026 session adjourned on May 3, 2026, the General Assembly’s last regular session. Bills that didn’t pass both chambers died.

What it does

This bill relates to direct acting antivirals, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission (commission). The bill prohibits the department of health and human services from requiring prior authorization for direct acting antiviral medications used to treat hepatitis C that are on the preferred drug list for the medical assistance program. The bill requires the commission to review, by July 1, 2026, the prescription drug vosevi for placement on the preferred drug list pursuant to U.S.C. §1396r-8 as a preferred direct acting antiviral for treatment of hepatitis C.

Sponsors

Sen. Zach Wahls (D)

Cost

No fiscal note

Senate subcommittee · named March 3, 2025

  • Sen. Mike Klimesh (R) · mike.klimesh@legis.iowa.gov
  • Sen. Mark Costello (R) · mark.costello@legis.iowa.gov
  • Sen. Zach Wahls (D) · zach.wahls@legis.iowa.gov

In plain words

  1. February 25, 2025Filed in the Senate and sent to the Health and Human Services committee
  2. March 3, 2025Senate subcommittee named: Klimesh, Costello and Wahls

From public records at legis.iowa.gov, compiled by Funnel (iowafunnel.com), an independent, nonpartisan site. Current as of Monday, November 9, 2026. https://iowafunnel.com/bills/91/SF433